Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Completed 1Active not recruiting 1

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2Endocrine 2Gynecologic 1Gastrointestinal 1

Conditions

Ovarian Neoplasms 93Small Cell Lung Carcinoma 74Neuroblastoma 44Carcinoma, Ovarian Epithelial 43Fallopian Tube Neoplasms 41Lung Neoplasms 39Neoplasms 29Uterine Cervical Neoplasms 26Leukemia 20Brain Neoplasms 18Leukemia, Myeloid, Acute 17Recurrence 16Sarcoma 15Precursor Cell Lymphoblastic Leukemia-Lymphoma 15Neoplasm Metastasis 13Lymphoma 12Central Nervous System Neoplasms 12Retinoblastoma 11Glioma 11Carcinoma, Non-Small-Cell Lung 11Sarcoma, Ewing 10Unspecified Adult Solid Tumor, Protocol Specific 8Neuroectodermal Tumors, Primitive, Peripheral 8Myelodysplastic Syndromes 8Medulloblastoma 8Endometrial Neoplasms 8Burkitt Lymphoma 8Lymphoma, Follicular 7Leukemia, Myelomonocytic, Chronic 7Blast Crisis 7

Interventions

Cisplatin 12Everolimus 10Nivolumab 8Etoposide 8Temozolomide 6Carboplatin 6atezolizumab 5Irinotecan 5Ipilimumab 5Fluorouracil 5Bevacizumab 5pembrolizumab 4lutetium Lu 177 dotatate 4Capecitabine 4avelumab 3Paclitaxel 3IFL protocol 3surufatinib 2sintilimab 2dostarlimab 2cabozantinib 2belinostat 2azaspirane 2Topotecan 2Radiosurgery 2Positron Emission Tomography Computed Tomography 2PE regimen 2N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 2Magnetic Resonance Imaging 2Leucovorin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Carcinoma, Neuroendocrine × Topotecan × Clear all
NCT04514497 2026-06-02

Testing the Addition of an Anti-cancer Drug, BAY 1895344, to Usual Chemotherapy for Advanced Stage Solid Tumors, With a Specific Focus on Patients With Small Cell Lung Cancer, Poorly Differentiated Neuroendocrine Cancer, and Pancreatic Cancer

National Cancer Institute (NCI)

Phase 1 Active not recruiting
29 enrolled 25 charts
EndocrineGastrointestinalThoracic

Lung Neoplasms, Neoplasm Metastasis, Pancreatic Neoplasms, Carcinoma, Neuroendocrine, Small Cell Lung Carcinoma

NCT02487095 2025-04-13

Trial of Topotecan With VX-970 (M6620), an ATR Kinase Inhibitor, in Small Cell Cancers and Extrapulmonary Small Cell Cancers

National Institutes of Health Clinical Center (CC)

Phase 1/2 Completed
62 enrolled 29 charts
EndocrineGynecologicThoracic

Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Ovarian Neoplasms, Carcinoma, Neuroendocrine, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡